It took decades for the cannabis to become legal for recreational use and there does not seem to be a time in the near future that you can just walk into a dispensary and purchase magic mushrooms in the same way as you would marijuana, but thanks to the tireless work of some advocates for psychedelic-assisted psychotherapy, psilocybin could be legal for medical use soon.
In this article, financial journalist Marc Davis discusses the mass [...]
A groundswell of public interest is building around a subset of hallucinogenic drugs whose primary effect is to trigger non-ordinary states of consciousness. Why? Because human beings are evolving
The psychedelic state induced by LSD appears to weaken the association between anatomical brain structure and functional connectivity, according to new research published in the journal NeuroImage.
An international online survey was conducted in 2018 examining people’s experiences of using psychedelics. Eligible participants were aged 16 years or older, had used psychedelics and could comprehend written English.
Researchers found that “their experience with psychedelic drugs was so powerful that they could recall and report on changes in symptoms from racial trauma that they had experienced in their lives, and they remembered it having a significant reduction in their mental health problems afterward,” said Davis.
The UK is experiencing a psychedelic renaissance. Young people in England and Wales are taking three times more LSD than they did five years ago, scientists at top universities are claiming hallucinogens can revolutionise how we treat mental illness and the use of magic mushrooms has been increasing by around 40 percent year on year.
Return of the lysergamides. Part I: Analytical and behavioral characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
1-Propionyl-d-lysergic acid diethylamide hemitartrate (1P-LSD) has become available as a ‘research chemical’ in form of blotters and powdered material.
In a November 2019 study published in Neuropharmacology, researchers tested whether the LSD(lysergic acid diethylamide) derivatives ALD-52 (1-acetyl-LSD), 1P-LSD (1-propanoyl-LSD), and 1B-LSD (1-butanoyl-LSD) are active compounds or prodrugs of LSD.
Microdosers take regular small doses of LSD or magic mushrooms. At these doses, they don’t experience mind-bending, hallucinatory trips, but they say they get a jolt in creativity and focus that can elevate work performance, help relationships, and generally improve a stressful and demanding daily life.